The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ The latest AI-powered cardiology devices you need to know
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
What a difference a day makes.
Yesterday Boston Scientific Corp. was fielding false claims and Medicare fraud charges.
Today the Natick, Mass.-based medical devices leviathan got word of a possible debt rating upgrade and said the Food & Drug Administration gave pre-market approval to its Taxus Liberté long stent.
Boston Scientific Corp. announced plans for a $128 million research & development lab in Galway, Ireland.
The Natick device maker, which already employs about 5,000 in Ireland, said the project will create roughly 45 jobs over five years, the Independent reported. The lab will focus on early-stage development projects.
CorNova Inc.‘s Valecor platinum coronary stent system won CE mark approval for sale in the European Union.
The Burlington-based device maker said the next-generation bare-metal device, made of cobalt-chromium using ion-based Nanofusion technology, presents a pure platinum surface to both the lumen and artery wall to protect them from the less-compatible elements inherent in medical-grade alloys.
The company is also developing balloon catheters designed to measure blood vessels from within the balloon during procedures.
Abbott Laboratories fired the latest salvo in the long-running stent war, saying it plans to begin selling its Xience Prime coronary device in Europe during the third quarter after winning CE Mark approval from the European Union.
The latest version of the Chicago-based medical device monolith’s drug-eluting Xience platform competes head-to-head with products from Natick-based peer Boston Scientific, Johnson & Johnson and Medtronic Inc.
The Food & Drug Administration gave the nod to Boston Scientific Corp.‘s small-vessel paclitaxel-eluting stent, the Taxus Liberté Atom, clearing the way for it to hit the market next month.
The federal watchdog agency cleared the device for treatment of coronary vessels as small as 2.25mm in diameter, making it and its Taxus Express Atom cousin the only two drug-eluting stents approved for procedures involving small vessels in the United States.
Boston Scientific Corp. started its first U.S. human trials of its Epic peripheral stent, even as rival Johnson & Johnson fired off another salvo in the stent wars.
The Natick-based stents giant is calling its new nickel-titanium alloy stent, designed to treat iliac artery disease, the “next generation” of nitinol device. The stent launched in Europe in April.
Boston Scientific Corp. can’t seem to catch a break.
Despite the publication of results from vairous clinical trials that show the superiority of drug-eluting stents — and, in one study, the superiority of the Natick device goliath’s DES over its competitors’ — its share price took a more than 2 percent dive today.
Nearly half of Boston Scientific Corp.‘s massive $6 billion-plus debt will come due in April 2011.
The company’s total tab is $6.25 billion, with an average interest rate of 5.84 percent. At the end of 2008, the company owed more than $6.78 billion, but has paid down about $500 million since January, at least some of it on the backs of Peter Nicholas and John Abele.
The BSC co-founders sold an enormous amount of personal stock in the company over the past six months.
Boston Scientific Corp. is touting a clinical trial comparing one of its drug-eluting stents with a bare-metal stent, published today in the New England Journal of Medicine.
If you’re judged by the company you keep, James Tobin, the CEO of Natick-based stents colossus Boston Scientific Corp. might want to skip this month’s copy of Forbes.
First-quarter sales for Boston Scientific Corp. slipped 1.8 percent to $2.01 billion, compared with $2.05 billion during the same period last year, as it struggles with a large chunk of long-term debt and fights expensive legal battles on a number of fronts.
The Natick-based devices giant plunged into the red, posting a $13 million net loss for the quarter ending March 31, compared with net income of $322 million during the first quarter of 2008.
